Skip to main content

The Globe and Mail

Possible treatment for a childhood brain tumour lacks funding for a clinical trial

Canadian researchers say they have made a key discovery that might explain how a rare and deadly childhood brain tumour develops, and they believe that existing drugs used to treat adults may slow or stop the tumour's growth. But they can't test their theory because they haven't been able to find funding for a clinical trial.

"As a clinician, it's very frustrating," said Dr. Annie Huang, an oncologist and brain tumour specialist at Toronto's Hospital for Sick Children, who helped lead the new research.

The brain tumour, known as ETMR/ETANTR, typically strikes children under age four and is extremely aggressive. Doctors try various drugs and radiation to treat the disease, but those treatments are usually ineffective. "Right now, literally it's almost a death sentence," Huang said. "More than 90 per cent of kids [diagnosed with the disease] will die."

Story continues below advertisement

After years of studying this vexing cancer, Huang and colleagues from McGill University Health Centre discovered that a certain gene is activated or "turned on" in children with this brain tumour, and it causes production of a specific enzyme. Their findings were published online this week in the journal Nature Genetics.

They believe the enzyme is tightly linked to the development of ETMR/ETANTR and fuels tumour growth. Huang said that means the key to helping children with this disease could be targeting the enzyme.

"If you can inhibit that enzyme, you can revert it back to normal," Huang said.

Their discovery is an important example of how epigenetics and personalized medicine are increasingly being used to find new ways to treat disease. Epigenetics refers to changes that can turn genes on or off. These changes can, among other things, spur tumour growth. The field of personalized medicine focuses on using an individual's specific genetic code to come up with a tailored medication or treatment that will work for them.

For patients and their families this is potentially significant because existing drugs can be used to target the enzyme, known as DNMT3B. The drugs are known as DNA methylation inhibitors, and researchers have already seen promising results from experiments using cancer cells collected from young patients.

The current treatment regimen for ETMR/ETANTR doesn't work on the majority of patients. The small number of patients that can be helped also face major side-effects that include intellectual and developmental impairment caused by the radiation and drugs.

In order to move forward, Huang and her colleagues want to test DNA methylation inhibitors on children with this rare brain tumour. Funding is difficult to secure because the tumours are so rare, Huang said. In these cases, international researchers typically team up to increase their chances of securing a clinical trial grant, but right now, it's unclear when the funding may come.

Story continues below advertisement

Report an error Licensing Options
About the Author

Carly Weeks has been a journalist with The Globe and Mail since 2007.  She has reported on everything from federal politics to the high levels of sodium in the Canadian diet. More

Comments

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨